Results 31 to 40 of about 184,022 (213)

Characterization of Common β-Thalassemia Major Mutations in Southwest Iran with Respect to Biochemical Parameters, Oxidative Status and Complications [PDF]

open access: yesJournal of Advanced Biomedical Sciences, 2021
Background & Objective: Beta-thalassemia are among the most common autosomal recessive genetic disorders in Iran, especially in Khuzestan province. Beta-thalassemia exhibits significant phenotype heterogeneity and there are currently more than 200 known ...
Hamid Yaghooti   +3 more
doaj  

Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling [PDF]

open access: yesIranian Journal of Basic Medical Sciences
Objective(s): Non-alcoholic fatty liver disease (NAFLD) is a chronic steatohepatitis disorder. If left untreated, it can progress to hepatocellular carcinoma.
Reza Afarin   +6 more
doaj   +1 more source

Up-regulated microRNA-185-3p inhibits the development of hyperlipidemia in rats

open access: yesKidney & Blood Pressure Research, 2022
Introduction: MicroRNA (miR)-185-3p functions in multiple cancers, while the underlying function of miR-185-3p in hyperlipidemia remained obscure. This research was conducted to unravel its function in hyperlipidemia development via modulating mastermind-
Hua Zhao, Yanbing Li
doaj   +1 more source

A new method for measurement of total plasma PCSK9: clinical applications

open access: yesJournal of Lipid Research, 2010
The proprotein convertase subtilisin kexin-9 (PCSK9) circulates in plasma as mature and furin-cleaved forms. A polyclonal antibody against human PCSK9 was used to develop an ELISA that measures total plasma PCSK9 rather than only the mature form. A cross-
Geneviève Dubuc   +10 more
doaj   +1 more source

Hypolipidemic effects of chitosan and its derivatives in hyperlipidemic rats induced by a high-fat diet

open access: yesFood & Nutrition Research, 2016
Background: Hyperlipidemia (HLP) is the primary risk factor of cardiovascular disease (CVD). Various factors, including genetics, physical inactivity, and daily nutritional habits, affect the prevalence of HLP.
Haitao Pan   +8 more
doaj   +1 more source

Anti-Obese Effect of Glucosamine and Chitosan Oligosaccharide in High-Fat Diet-Induced Obese Rats

open access: yesMarine Drugs, 2015
Objective: This study is to evaluate the anti-obese effects of glucosamine (GLC) and chitosan oligosaccharide (COS) on high-fat diet-induced obese rats. Methods: The rats were randomly divided into twelve groups: a normal diet group (NF), a high-fat diet
Lanlan Huang   +8 more
doaj   +1 more source

Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state

open access: yesJournal of Lipid Research, 2000
Potentially atherogenic triglyceride-rich lipoprotein (TRL) remnants can be isolated and quantitated as remnant-like particles (RLP), using an immunoaffinity gel containing specific anti-human apolipoprotein A-I (apoA-I) and apoB-100 monoclonal ...
Caroline Marcoux   +6 more
doaj   +1 more source

A cross-sectional study exploring the relationship between the dietary inflammatory index and hyperlipidemia based on the National Health and Nutrition Examination Survey (2005–2018)

open access: yesLipids in Health and Disease, 2023
Background Hyperlipidemia is closely associated with dietary patterns and inflammation. However, the relationship between hyperlipidemia and the inflammatory potential of diets remains unexplored.
Yu Han   +5 more
doaj   +1 more source

Hyperlipidemia in Patients with Calcific Tendinitis

open access: yes, 2022
Objective: Calcific tendinitis is a disease of unclear etiology and is associated with metabolic diseases. Hyperlipidemia, one of the metabolic diseases with systemic effects, may be associated with tendinopathy and tendinitis. In this study, we aimed to
Yuce, Elif Ilkay   +3 more
core   +1 more source

Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia

open access: yesJournal of Lipid Research, 2002
Atorvastatin, a synthetic HMG-CoA reductase inhibitor used for the treatment of hyperlipidemia and the prevention of coronary artery disease, significantly lowers plasma cholesterol and low-density lipoprotein cholesterol (LDL-C) levels.
Jeffrey S. Cohn   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy